A Phase 4 interventional study of Ketorolac and Control (Standard treatment) in Femoracetabular Impingement and Hip Arthroscopy, sponsored by Henry Ford Health System. Recruiting at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Henry Ford Health System · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Femoracetabular Impingement with a site in United States — 10 open to participants now, 15 under way, 1 of them phase 3. Femoracetabular Impingement · United States.
Among the 37 studies in Femoracetabular Impingement with a site in United States, this one is the 6th largest by planned enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2023, is one of 6 in phase 4, reaches primary completion later than 6 of the 14 other live ones, and was the 37th registered.
116 studies on the registry are indexed under Femoracetabular Impingement; 37 are open to participants now.
Browse Femoracetabular Impingement studies →10 of the 37 studies in Femoracetabular Impingement with a site in United States are open now. Recruiting first, the newest first:
American Hip Institute · Sites in United States
Ages 18–60
University of Missouri-Columbia · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Rush University Medical Center · Sites in United States
Ages 18–40 · Healthy volunteers
Yale University · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Femoracetabular Impingement studies recruiting now, 6 (30%) set no upper age limit and 12 (60%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 2 · Phase 4 6
First in 2012; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 73 across 70 interventional studies indexed under Femoracetabular Impingement.
Median enrollment 62 across the 28 interventional studies, 88 across the 9 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 37 have an industry lead sponsor. The 10 most frequent:
Henry Ford Health System is the lead sponsor of 304 studies on the registry; 51 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 26 (70%) have results posted.
Henry Ford Health System has 1 study filed under Femoracetabular Impingement — fewer than ten, so there is no comparison to draw.
5 of the studies in Femoracetabular Impingement with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06003101Phase 3Massachusetts General HospitalEffect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies | 2027-08-30 |
| NCT07037888Henry Ford Health SystemEfficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy | 2026-12 |
| NCT02664337Duke UniversityConjoint Analysis of Patient Preferences in Joint Interventions | 2027-07 |
| NCT04094701Rush University Medical CenterHip Arthroscopy Postoperative Opioid Demands | 2027-11 |
| NCT04113759Rush University Medical CenterBlood Flow Restriction Following Hip Arthroscopy | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 37 studies in Femoracetabular Impingement with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether the medication ketorolac can help manage pain after hip arthroscopy as well or better than the standard opioid-based pain medications. This study focuses on adult patients (over 18 years old) undergoing hip arthroscopy at Henry Ford Health System in Detroit, Michigan. Both men and women are included, and all participants must be able to consent and communicate in English.
The main questions it aims to answer are:
Can ketorolac help control pain as effectively or better than opioids after hip arthroscopy?
Will ketorolac use reduce the amount of opioid medication needed after surgery?
Researchers will compare the group receiving ketorolac to the group receiving standard opioid pain medications to see if ketorolac reduces pain and opioid use after surgery.
Participants will:
Be randomly assigned to one of two groups:
The control group, which receives the current standard pain management protocol (hydrocodone-acetaminophen and diazepam)
The experimental group, which receives the same protocol plus ketorolac and a stomach-protecting medication (omeprazole)
Receive their assigned pain medications after hip arthroscopy
Be asked to:
Take the prescribed medications after discharge
Complete a pain journal for 5 days following surgery, documenting pain levels and any side effects
Complete follow-up surveys and assessments at 2 weeks, 6 weeks, and 3 months after surgery
The main measurement researchers will use is the Visual Analog Scale (VAS) for pain on post-operative day 4. Additional measures include how many narcotic pills are used and results from PROMIS physical function and pain interference scores.
The hope is that ketorolac will provide equal or better pain control without the risks of addiction and side effects associated with opioid medications. If successful, this approach could offer a safer alternative for managing pain after hip arthroscopy. Participants may personally benefit by having effective pain relief with fewer risks, and future patients could benefit from improved pain management options.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard of care/control pain protocol
Drug: Control (Standard treatment)
Intra-operative IV and Oral doses of Ketorolac plus Standard of care
Drug: Ketorolac · Drug: Control (Standard treatment) · Drug: Omeprazole
IV ketorolac intraoperative loading dose Ketorolac 10mg 1 tablet q6hrs to start on POD0
hydrocodone-acetaminophen 5mg/325mg 1 tablet q6hrs PRN to start on POD0 30 tablets
indomethacin 75mg 1 tablet QD to start on POD0 10 tablets
diazepam 5mg 1-2 tablets q8hrs PRN to start on POD0 15 tablets
20 mg qd
Visual Analogue Scale (VAS)
A validated tool used to help a person rate the intensity of certain sensations and feelings, such as pain. The visual analog scale for pain is a straight line with the far-left end meaning no pain and the far-right end meaning the worst pain imaginable. A patient marks a point on the line that matches the amount of pain he or she feels. It may be used to help choose the right dose of pain medicine.
Time frame: 5 days
PROMOIS- PF
This is a standardized patient-reported outcome measure that assesses an individual's self-reported capability to perform physical activities, including both basic activities of daily living (ADLs) and instrumental activities of daily living (IADLs). It utilizes a T-score scale, mean = 50, standard deviation = 10, and higher scores indicate greater physical function.
Time frame: 2 weeks, 6 weeks, 3 months
PROMOIS- PI
a patient-reported outcome measure that assesses the extent to which pain hinders a person's engagement in various activities. It utilizes a T-score scale, mean = 50, standard deviation = 10, and higher scores indicate greater interference from pain.
Time frame: 2 weeks, 6 weeks, 3 months
Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ketorolac · Omeprazole